In contrast, at physiological levels of EPO (without exogenous EPO administration), cKD an control mice had similar fraction of CD115+ Pro-B (data not shown), whereas the former exhibited significantly lower RANKL mRNA levels (Figure 4G), consistent with a bone phenotype. This evidence concerns the gene EPO and chronic kidney disease.